Blueprint Medicines to Expand Precision Therapy Leadership in Lung Cancer with Acquisition of Lengo…
Blueprint Medicines Corporation announced that the company has entered into a definitive agreement under which it will acquire Lengo Therapeutics, a privately held precision oncology…
Read More...
Read More...
